News
-
Inhaled mRNA developer Ethris and CDMO Evonik have announced a new partnership for development and commercialization of a lipid nanoparticle (LNP) platform for delivery of nucleic acid. Ethris’s SNaP LNP technology will become available to… Read more . . .
-
Strides Pharma Science announced a new development agreement between Strides Pharma Global and OINDP specialist CDMO Kenox Pharmaceuticals for “multiple nasal spray products for the US market across diverse therapeutic indications.” The company did not… Read more . . .
-
According to Pulmovant, the Japanese Ministry of Health, Labour and Welfare (MHLW) has granted orphan drug designation to Pulmovant’s inhaled dry powder mosliciguat for the treatment of pulmonary hypertension associated with interstitial lung disease (PH-ILD).… Read more . . .
-
Phase 2 study finds azelastine nasal spray significantly reduced SARS-CoV-2 and rhinovirus infection
Saarland University announced that the Phase 2 CONTAIN study of azelastine nasal spray as a prophylactic against SARS-CoV-2 demonstrated a significant reduction in SARS-CoV-2 infection and also a reduction in rhinovirus infection for subjects using… Read more . . .
-
SpliSense has announced results from the Phase 2 SPL84-002 study of SPL84 inhaled antisense oligonucleotide (ASO) for the treatment of people with cystic fibrosis who carry the 3849+10 Kb C->T mutation in the CFTR gene. The… Read more . . .
-
According to SoftOx Solutions, the company intends to conduct a Phase 1 proof-of-concept dose escalation study of SoftOx inhalation solution (SIS) in cystic fibrosis patients as part of a refocus away from development of SIS… Read more . . .
-
United Therapeutics announced that the Phase 3 TETON-2 trial of nebulized Tyvaso treprostinil inhalation solution in patients with idiopathic pulmonary fibrosis met its primary efficacy endpoint, demonstrating a 95.6 mL change in absolute FVC from baseline to… Read more . . .
-
Inhaled epinephrine developer De Motu Cordis (DMC) announced that its CEO Peter O’Neill has stepped down and that Chief Financial Officer John Corbett will serve as Interim CEO. The company says that it is preparing… Read more . . .
-
Australian inhaled drug developer InhaleRx announced that it has received approval from the Bellberry Human Research Ethics Committee for a Phase 1 trial of its IRX-616a MDI, which the company is developing for the treatment… Read more . . .
-
According to MannKind Corporation, United Therapeutics has exercised an option granted under a 2018 licensing and collaboration agreement between the companies for development of an additional dry powder inhalation product based on MannKind’s Technosphere technology. The… Read more . . .
Upcoming Events
Sponsored by Intertek
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
October 19-October 20: MVIC Autumn Training 2026, Lund, Sweden
October 21-October 22: MVIC Symposium, Lund, Sweden
November 10-November 11: Rescon Europe 2026, Porto, Portugal
December 9-December 11: DDL 2026, Edinburgh, Scotland